According to a New Study Published in the European Journal of Pharmaceutical Sciences, NOXO Sensory Ingredients are Shown to be Absorbed through the Olfactory Receptors which are Positioned at the Front of the Underside of the Brain. Once the Medicine Passes the Olfactory Receptors, there is Direct Access to the Brain
PHILADELPHIA, PA / ACCESSWIRE / January 17, 2018 / Olfactory Biosciences Corp. (OTC PINK: OLFC) is pleased to announce the new and improved NOXO Sensory Spectrum Disorders Gel™. http://sensory-control.com/
Sensory Spectrum Disorder Gel™ is a topical preparation for people with sensory integration difficulties, especially those with autism spectrum disorder (ASD).
Sensory Spectrum Disorder Gel™ is topical medicine made with natural ingredients. Simply applying a small amount of Sensory Spectrum Disorder Gel™ topical medicine to the end of the nostrils and inhaling immediately, people with hypersensitivities to smells in the environment as well as other sensory issues, are helped using advanced olfaction and chemoreception, the Gel's olfactory molecules transport their messages directly to the brain's limbic system, the "emotional brain," alleviating distress and dysregulation due to environmental smells. http://sensory-control.com/
Ingredients: A special proprietary formulation of Phytonutrients and Phytochemicals taken from plants, flowers, roots, and seeds. All ingredients are in a soy base which is FDA approved for cosmetic use. The specific chemical identities of the ingredients in this mixture are considered by us to be trade secrets and are withheld in accordance with the provisions of the 1910.1200 of the Code of Federal Regulations.
For Information and website: http://sensory-control.com/.
FORWARD-LOOKING STATEMENTS: "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 :Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding sales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Contact:
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Phone: 484-278-1626
Website: http://sensory-control.com/
E-mail: [email protected]
SOURCE: Olfactory Biosciences Corp.